3.56

0.28% -0.010

Neuphoria Therapeutics Inc (NEUP)

Overview News Price History Discussions Forecast

Neuphoria Therapeutics Inc stock is traded at $3.56, with a volume of 10,391. It is down -0.28% in the last 24 hours and down -5.32% over the past month. Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Previous Close:

$3.57

Open:

$3.5995

24h Volume:

10,391

Relative Volume:

0.06

Market Cap:

$19.26M

Revenue:

$15.00M

Net Income/Loss:

$2.71M

P/E Ratio:

2.7976

EPS:

1.2725

Net Cash Flow:

$-2.89M

1W Performance:

-3.26%

1M Performance:

-5.32%

6M Performance:

-12.53%

1Y Performance:

-69.80%

1-Day Range:

$3.53

$3.615

1-Week Range:

$3.53

$3.6995

52-Week Range:

$3.19

$21.40

Neuphoria Therapeutics Inc Stock (NEUP) Company Profile

Name

Neuphoria Therapeutics Inc

Sector

Healthcare (1062)

Industry

Biotechnology (595)

Phone

781-439-5551

Address

100 SUMMIT DR, BURLINGTON

Employee

Twitter

Next Earnings Date

2026-11-13

Latest SEC Filings

NEUP's Discussions on Twitter

Compare NEUP vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NEUP Neuphoria Therapeutics Inc	3.56	19.75M	15.00M	2.71M	-2.89M	1.2725
VRTX Vertex Pharmaceuticals Inc	522.81	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	758.27	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	192.57	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	958.91	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	205.26	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-28-23	Reiterated	Maxim Group	Buy
Jan-10-22	Initiated	Berenberg	Buy
Jan-10-22	Initiated	Cantor Fitzgerald	Overweight
Jan-10-22	Initiated	Evercore ISI	Outperform
Jan-10-22	Initiated	H.C. Wainwright	Buy

View All

Neuphoria Therapeutics Inc Stock (NEUP) Latest News

Sep 24, 2026

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership - stocktwits.com

Sep 24, 2026

Sep 21, 2026

Accenture, Abivax and 3 Stocks to Watch Heading Into Monday - Benzinga

Sep 21, 2026

Sep 19, 2026

Neuphoria to Be Acquired by Scancell in All-Stock Merger - Minichart

Sep 19, 2026

Sep 18, 2026

Neuphoria Therapeutics Q4 Results: EPS misses estimate, losses widen 76% - scanx.trade

Sep 18, 2026

Neuphoria Therapeutics Inc. FY 2026: Revenue $1.17M, Net loss $13.59M — 10-K Summary - TradingView

Sep 18, 2026

NEUP: FY26 saw a sharp revenue drop, major restructuring, and a $5.4M goodwill impairment amid a pending merger - TradingView

Sep 18, 2026

NEUP Stock Price and Chart — NASDAQ:NEUP - TradingView

Sep 18, 2026

Sep 04, 2026

Neuphoria Therapeutics Inc (NASDAQ: NEUP) Share Price, NEUP Stock News, NEUP Share Price & Updates - Kalkine

Sep 04, 2026

Sep 01, 2026

NEUP Q4'26 Earnings: EPS estimate is (0.56) USD - TradingView

Sep 01, 2026

Aug 23, 2026

Neuphoria (NEUP) EPS and Revenue: Reported EPS Tops Expectations for the Current Session; Share Move: Shares Move Lower 1.01% in the Available RecordGross Profit Margin - dars.gov.et

Aug 23, 2026

Aug 14, 2026

ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView

Aug 14, 2026

Aug 11, 2026